2018 ACAAI/AAAAI Joint Board Review Certification Course ONLINE PARENTFORMAT

We believe you will find the 2018 ACAAI/AAAAI Joint Board Certification Review Course Online to be a valuable resource in preparation for the upcoming certification exam as well as for planning future strategies in practice.


2018 Course Co-Chairs:  David A. Khan, MD and Thomas A. Fleisher, MD

Target Audience

  • Fellows-in-Training preparing for upcoming certification exams
  • Practicing Allergists looking for an intensive review of the key principles in allergy/immunology

Learning Objectives

At the conclusion of this course, participants should be able to:

  • Identify, evaluate and manage current concerns and issues related to the pathophysiology, diagnosis and treatment of allergic and immunologic diseases.
  • Demonstrate a mastery of key concepts in allergy and immunology.
  • Summarize the practical application of key concepts in allergy and immunology in the management of clinical problems



The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 18.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Commercial Support
There is no commercial support for this activity.

Additional information

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. The ACCME defines a “commercial interest” as any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations.

All identified conflicts of interest have been resolved:

David Khan, MD, Co-Chair, Planner, Reviewer, Speaker
Data Safety Monitoring Committee, Honorarium: Aimmune
Speaker, Honorarium: Genentech

Mark Ballow, MD, Speaker
Advisory Board, Honorarium: CSL Behring, Shire
Data Safety Monitoring Board, Fees: CSL Behring, Green Cross, Prometic
Speaker, Honorarium: CSL Behring, Shire

Carla Davis, MD, Speaker
Advisory Board, Research Funding: Aimmune Therapeutics
Research, Research Funding: Aimmune Therapeutics, DBV, Nutricia North America

David Lang, MD, Planner, Reviewer, Speaker
Consultant, Fees: Genentech/Novartis, Hycor
Independent Contractor (Topic Editor), Fees: Dynamed
Research, Research Funding: Genentech/Novartis
Speaker, Honorarium: AstraZeneca, Genentech/Novartis

Carol Langford, MD, MHS, Speaker
Research, Research Funding: Bristol Myers Squibb, ChemoCentryx, Genentech, GlaxoSmithKline

Jordan Orange, MD, PhD, Speaker
Advisory Board, Fees: ADMA Biologics
Consultant, Fees: CSL Behring, Shire
Speaker, Honorarium: Shire

Anju Peters, MD, Speaker
Advisory Board, Honorarium: Optinose, Sanofi
Research, Research Funding: AstraZeneca, Sanofi
Speaker, Honorarium: Greer

John Routes, MD, Planner, Reviewer, Speaker
Research, Research Funding: CSL Behring

Troy Torgerson, MD, Speaker
Consultant, Fees: ADMA Biosciences, CSL Behring, Shire, UCB Biopharmaceuticals
Research, Research Funding: CSL Behring, Shire

The following have no financial relationships to disclose:

Thomas Fleisher, MD, Co-Chair, Planner, Reviewer, Speaker
Karyl Barron, MD, Speaker
Anthony Gaspari, MD, Speaker
Matthew Giannetti, MD, Speaker
Steven Holland, MD, Speaker
Paneez Khoury, MD, Speaker
Sergio Rosenzweig, MD, Speaker
Mark Sands, MD, Speaker
Robert Schleimer, PhD, Speaker
Joseph Spahn, MD, Speaker
Kelly Stone, MD, PhD, Planner, Reviewer, Speaker
Kate Sullivan, MD, Planner, Reviewer
Mike Tankersley, MD, Speaker
J. Tom Thomas, II, MD, Speaker

Course summary
Course opens: 
Course expires: 
Please login or create an account to take this course.
Please login or create an account to take this course.


Please login or create an account to take this course.